Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-center cohort.

Our study confirms that ppFVC is a marker of survival in SSc-ILD, supporting its use for risk stratification to identify patients who may benefit from earlier interventions and treatment. Our study also supports the role of ATA positivity as a predictive marker for ppFVC decline in this population.